Вопросы вирусологии. 2020; 65: 167-175
Применение ингибиторов вирусных РНК-полимераз в сочетании с ингибитором фузии в лечении пациентов с COVID-19: гипотеза
https://doi.org/10.36233/0507-4088-2020-65-3-167-175Аннотация
В статье рассматриваются возможности комбинированной противовирусной терапии пациентов с COVID-19 на основании анализа механизма действия известных противовирусных препаратов в рамках медицинской гипотезы. Обсуждается потенциальная эффективность совместного применения ингибиторов вирусных РНК-полимераз (рибавирина, риамиловира, фавипиравира) и ингибитора фузии при данной патологии (умифеновира). Проанализирован профиль эффективности и безопасности данных препаратов, в том числе опыт их применения в клинических исследованиях, проведённых в период пандемии COVID-19, а также во время эпидемий SARS и MERS.
Список литературы
1. Временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). Available at: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf
2. Fan H.H., Wang L.Q., Liu W.L., An X.P., Liu Z.D., He X.Q., et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin. Med. J. (Engl.). 2020; 133(9): 1051-6. DOI: http://doi.org/10.1097/CM9.0000000000000797
3. Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238): 1695-704. DOI: http://doi.org/10.1016/S0140-6736(20)31042-4
4. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., et al. Compassionate use of Remdesivir for patients with severe Covid-19. N. Engl. J. Med. 2020; 382(24): 2327-36. DOI: http://doi.org/10.1056/NEJMoa2007016
5. Leyssen P., De Clercq E., Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 2006; 69(4): 1461-7. DOI: http://doi.org/10.1124/mol.105.020057
6. Crotty S., Cameron C., Andino R. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. (Berl). 2002; 80(2): 86- 95. DOI: http://doi.org/10.1007/s00109-001-0308-0
7. Рибавирин (Ribavirinum): инструкция, применение, противопоказания и формула. Available at: http://www.rlsnet.ru/mnn_index_id_288.htm (Дата обращения: 15.05.2020)
8. Zhurilo N.I., Chudinov M.V., Matveev A.V., Smirnova O.S., Konstantinova I.D., Miroshnikov A.I., et al. Isosteric ribavirin analogues: Synthesis and antiviral activities. Bioorg. Med. Chem. Lett. 2018; 28(1): 11-4. DOI: http://doi.org/10.1016/j.bmcl.2017.11.029
9. Uematsu J., Sakai-Sugino K., Kihira-Nakanishi S., Yamamoto H., Hirai K., Kawano M., et al. Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine. Drug Discov. Ther. 2019; 13(6): 314-21. DOI: http://doi.org/10.5582/ddt.2019.01084
10. Khalili J.S., Zhu H., Mak N.S.A., Yan Y., Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol. 2020; 92(7): 740-6. DOI: http://doi.org/10.1002/jmv.25798
11. Omrani A.S., Saad M.M., Baig K., Bahloul A., Abdul-Matin M., Alaidaroos A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 2014; 14(11): 1090-5. DOI: http://doi.org/10.1016/S1473-3099(14)70920-X
12. Falzarano D., de Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 2013; 3: 1686. DOI: http://doi.org/10.1038/srep01686
13. Zhong H., Wang Y., Zhang Z.L., Liu Y.X., Le K.J., Cui M., et al. Efficacy and safety of current therapeutic options for COVID-19 – lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol. Res. 2020; 157: 104872. DOI: http://doi.org/10.1016/j.phrs.2020.104872
14. Karpenko I., Deev S., Kiselev O., Charushin V., Rusinov V., Ulomsky E., et al. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob. Agents Chemother. 2010; 54(5): 2017-22. DOI: http://doi.org/10.1128/AAC.01186-09
15. Чупахин О.Н., Киселёв О.И., ред. Триазавирин – противовирусный препарат нового поколения. Екатеринбург; 2016.
16. Shvetsov A.V., Zabrodskaya Y.A., Nekrasov P.A., Egorov V.V. Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. J. Biomol. Struct. Dyn. 2018; 36(10): 2694-8. DOI: http://doi.org/10.1080/07391102.2017.1367329
17. Логинова С.Я., Борисевич С.В., Максимов В.А., Бондарев В.П., Котовская С.К., Русинов В.Л. и др. Лечебная эффективность нового отечественного химиопрепарата Триазавирин в отношении возбудителя гриппа A (H5N1). Антибиотики и химиотерапия. 2011; 56(1-2): 10-2.
18. Логинова С.Я., Борисевич С.В., Русинов В.Л., Уломский Е.Н., Чарушин В.Н., Чупакин О.Н. и др. Изучение лечебной эффективности триазавирина в отношении экспериментальной формы клещевого энцефалита у белых мышей. Антибиотики и химиотерапия. 2015; 60(7-8): 11-3.
19. Смирнова Т.Д., Даниленко Д.М., Еропкин М.Ю., Деева Е.Г., Кисилев О.И. Изучение влияния ремантадина, рибавирина и триазавирина на репродукцию вирусов гриппа А в монослойных и лимфобластоидных линиях человеческого происхождения. Антибиотики и химиотерапия. 2011; 56(11-12): 11-6.
20. Киселев О.И., Деева Е.Г., Мельникова Т.И., Козелетская К.Н., Киселев А.С., Русинов В.Л. и др. Новый отечественный препарат триазавирин. Результаты II фазы клинического испытания. Вопросы вирусологии. 2012; 57(6): 9-12.
21. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2011; 25(1). Available at: https://www.who.int/medicines/publications/druginformation/innlists/RecList65_final.pdf (Accessed 15.04.2020)
22. Умифеновир (Umifenovirum): инструкция, применение, противопоказания и формула. Available at: https://www.rlsnet.ru/mnn_index_id_6264.htm (Дата обращения: 15.04.2020)
23. Ligen Y. Handbook of COVID-19 Prevention and Treatment; 2020. Available at: https://www.researchgate.net/publication/339998871_Handbook_of_COVID-19_Prevention_and_Treatment (Accessed 15.04.2020)
24. Пшеничная Н.Ю., Булгакова В.А., Львов Н.И., Поромов А.А., Селелкова Е.П., Грекова А.И. и др. Клиническая эффективность умифеновира при гриппе и ОРВИ (исследование АРБИТР). Терапевтический архив. 2019; 91(3): 56-63. DOI: http://doi.org/10.26442/00403660.2019.03.000127
25. Haviernik J., Štefánik M., Fojtíková M., Kali S., Tordo N., Rudolf I., et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018; 10(4): 184. DOI: http://doi.org/10.3390/v10040184
26. Zhang S., Zhi C., Li H., Huang D., Fan Q., Cui J., Umifenovir effectively inhibits IL-10 dependent persistent Coxsackie B4 virus infection. Antiviral. Res. 2017; 141: 165-73. DOI: http://doi.org/10.1016/j.antiviral.2017.02.018
27. Zhu Z., Lu Z., Xu T., Chen C., Yang G., Zha T., et al. Arbidol monotherapy is superior to Lopinavir/ritonavir in treating COVID-19. J. Infect. 2020; 81(1): e21-3. DOI: http://doi.org/10.1016/j.jinf.2020.03.060
28. Временные методические рекомендации. Лекарственная терапия острых респираторных вирусных инфекций (ОРВИ) в амбулаторной практике в период эпидемии COVID-19. Версия 1 (12.04.2020). М.; 2020. Available at: https://static-3.rosminzdrav.ru/system/attachments/attaches/000/049/991/original/RESP_REC_V1.pdf (Дата обращения: 15.04.2020)
29. Du Y.X., Chen X.P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 2020. DOI: http://doi.org/10.1002/cpt.1844
30. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards influenza a virus polymerase. PLoS One. 2013; 8(7): e68347. DOI: http://doi.org/10.1371/journal.pone.0068347
31. Справочник лекарств Medum.ru. АВИФАВИР – инструкция по применению. Available at: http://medum.ru/avifavir (Дата обращения: 06.06.2020)
32. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 2002; 46(4): 977-81. DOI: http://doi.org/10.1128/aac.46.4.977-981.2002
33. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020; 209: 107512. DOI: http://doi.org/10.1016/j.pharmthera.2020.107512
34. Baranovich T., Wong S.S., Armstrong J., Marjuki H., Webby R.J., Webster R.G., et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 2013; 87(7): 3741-51. DOI: http://doi.org/10.1128/JVI.02346-12
35. Escribano-Romero E., Jiménez de Oya N., Domingo E., Saiz J.C. Extinction of West Nile virus by favipiravir through lethal mutagenesis. Antimicrob. Agents Chemother. 2017; 61(11): e01400-17. DOI: http://doi.org/10.1128/AAC.01400-17
36. Rosenke K., Feldmann H., Westover J.B., Hanley P.W., Martellaro C., Feldmann F., et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg. Infect. Dis. 2018; 24(9): 1696-9. DOI: http://doi.org/10.3201/eid2409.180233
37. Mendenhall M., Russell A., Smee D.F., Hall J.O., Skirpstunas R., Furuta Y., et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl. Trop. Dis. 2011; 5(10): e1342. DOI: http://doi.org/10.1371/journal.pntd.0001342
38. Kerber R., Lorenz E., Duraffour S., Sissoko D., Rudolf M., Jaeger A., et al. Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study. J. Infect. Dis. 2019; 220(2): 195-202. DOI: http://doi.org/10.1093/infdis/jiz078
39. Cohen J. Results from encouraging Ebola trial scrutinized. Science. 2015. DOI: http://doi.org/doi:10.1126/science.aaa7912 Available at: https://www.sciencemag.org/news/2015/02/results-encouraging-ebola-trial-scrutinized (Accessed 06.06.2020)
40. Nguyen T.H., Guedj J., Anglaret X., Laouénan C., Madelain V., Taburet A.M., et al. JIKI study group. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis. 2017; 11(2): e0005389. DOI: http://doi.org/10.1371/journal.pntd.0005389
41. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271. DOI: http://doi.org/10.1038/s41422-020-0282-0
42. Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 2020; 19(3): 149-50. DOI: http://doi.org/10.1038/d41573-020-00016-0
43. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020. DOI: http://doi.org/10.1016/j.eng.2020.03.007
44. Irie K., Nakagawa A., Fujita H., Tamura R., Eto M., Ikesue H., et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin. Transl. Sci. 2020. DOI: http://doi.org/10.1111/cts.12827
45. Реестр разрешений на проведение клинических исследований: ЛП Фавипиравир. Available at: https://grls.rosminzdrav.ru/CiPermitionReg.aspx?PermYear=0&DateInc=&NumInc=&DateBeg=&-DateEnd=&Protocol=&RegNm=&Statement=&ProtoNum=&idCIStatementCh=&Qualifier=&CiPhase=&RangeOfApp=&Torg=%d0%a4%d0%b0%d0%b2%d0%b8%d0%bf%d0%b8%d1%80%d0%b0%d0%b2%d0%b8%d1%80&LFDos=&Producer=&Recearcher=&sponsorCountry=&MedBaseCount=&CiType=&PatientCount=&OrgDocOut=2&Status=&NotInReg=0&All=0&PageSize=8&order=date_perm&orderType=desc&pagenum=1 (Дата обращения: 06.06.2020)
46. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J. Virus. Erad. 2020; 6(2): 45-51.
47. Al-Tawfiq J.A., Momattin H., Dib J., Memish Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 2014; 20: 42-6. DOI: http://doi.org/10.1016/j.ijid.2013.12.003
Problems of Virology. 2020; 65: 167-175
The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis
https://doi.org/10.36233/0507-4088-2020-65-3-167-175Abstract
This review article considers the possibilities of combined antiviral therapy in the treatment of patients with COVID-19, based on the analysis of the mechanism of action of known antiviral drugs in the framework of the medical hypothesis. The potential effectiveness of the joint use of viral RNA polymerase inhibitors and a fusion inhibitor in this pathology is discussed. The review discusses the main representatives of these groups of drugs – ribavirin, riamilovir, umifenovir, favipiravir. The efficacy and safety profile of these drugs was analyzed, including the experience of their use in clinical trials conducted during the COVID-19 pandemic, as well as earlier work performed during the SARS and MERS epidemics.
References
1. Vremennye metodicheskie rekomendatsii profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiya 6 (28.04.2020). Available at: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf
2. Fan H.H., Wang L.Q., Liu W.L., An X.P., Liu Z.D., He X.Q., et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin. Med. J. (Engl.). 2020; 133(9): 1051-6. DOI: http://doi.org/10.1097/CM9.0000000000000797
3. Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238): 1695-704. DOI: http://doi.org/10.1016/S0140-6736(20)31042-4
4. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., et al. Compassionate use of Remdesivir for patients with severe Covid-19. N. Engl. J. Med. 2020; 382(24): 2327-36. DOI: http://doi.org/10.1056/NEJMoa2007016
5. Leyssen P., De Clercq E., Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 2006; 69(4): 1461-7. DOI: http://doi.org/10.1124/mol.105.020057
6. Crotty S., Cameron C., Andino R. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. (Berl). 2002; 80(2): 86- 95. DOI: http://doi.org/10.1007/s00109-001-0308-0
7. Ribavirin (Ribavirinum): instruktsiya, primenenie, protivopokazaniya i formula. Available at: http://www.rlsnet.ru/mnn_index_id_288.htm (Data obrashcheniya: 15.05.2020)
8. Zhurilo N.I., Chudinov M.V., Matveev A.V., Smirnova O.S., Konstantinova I.D., Miroshnikov A.I., et al. Isosteric ribavirin analogues: Synthesis and antiviral activities. Bioorg. Med. Chem. Lett. 2018; 28(1): 11-4. DOI: http://doi.org/10.1016/j.bmcl.2017.11.029
9. Uematsu J., Sakai-Sugino K., Kihira-Nakanishi S., Yamamoto H., Hirai K., Kawano M., et al. Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine. Drug Discov. Ther. 2019; 13(6): 314-21. DOI: http://doi.org/10.5582/ddt.2019.01084
10. Khalili J.S., Zhu H., Mak N.S.A., Yan Y., Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol. 2020; 92(7): 740-6. DOI: http://doi.org/10.1002/jmv.25798
11. Omrani A.S., Saad M.M., Baig K., Bahloul A., Abdul-Matin M., Alaidaroos A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 2014; 14(11): 1090-5. DOI: http://doi.org/10.1016/S1473-3099(14)70920-X
12. Falzarano D., de Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 2013; 3: 1686. DOI: http://doi.org/10.1038/srep01686
13. Zhong H., Wang Y., Zhang Z.L., Liu Y.X., Le K.J., Cui M., et al. Efficacy and safety of current therapeutic options for COVID-19 – lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol. Res. 2020; 157: 104872. DOI: http://doi.org/10.1016/j.phrs.2020.104872
14. Karpenko I., Deev S., Kiselev O., Charushin V., Rusinov V., Ulomsky E., et al. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob. Agents Chemother. 2010; 54(5): 2017-22. DOI: http://doi.org/10.1128/AAC.01186-09
15. Chupakhin O.N., Kiselev O.I., red. Triazavirin – protivovirusnyi preparat novogo pokoleniya. Ekaterinburg; 2016.
16. Shvetsov A.V., Zabrodskaya Y.A., Nekrasov P.A., Egorov V.V. Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. J. Biomol. Struct. Dyn. 2018; 36(10): 2694-8. DOI: http://doi.org/10.1080/07391102.2017.1367329
17. Loginova S.Ya., Borisevich S.V., Maksimov V.A., Bondarev V.P., Kotovskaya S.K., Rusinov V.L. i dr. Lechebnaya effektivnost' novogo otechestvennogo khimiopreparata Triazavirin v otnoshenii vozbuditelya grippa A (H5N1). Antibiotiki i khimioterapiya. 2011; 56(1-2): 10-2.
18. Loginova S.Ya., Borisevich S.V., Rusinov V.L., Ulomskii E.N., Charushin V.N., Chupakin O.N. i dr. Izuchenie lechebnoi effektivnosti triazavirina v otnoshenii eksperimental'noi formy kleshchevogo entsefalita u belykh myshei. Antibiotiki i khimioterapiya. 2015; 60(7-8): 11-3.
19. Smirnova T.D., Danilenko D.M., Eropkin M.Yu., Deeva E.G., Kisilev O.I. Izuchenie vliyaniya remantadina, ribavirina i triazavirina na reproduktsiyu virusov grippa A v monosloinykh i limfoblastoidnykh liniyakh chelovecheskogo proiskhozhdeniya. Antibiotiki i khimioterapiya. 2011; 56(11-12): 11-6.
20. Kiselev O.I., Deeva E.G., Mel'nikova T.I., Kozeletskaya K.N., Kiselev A.S., Rusinov V.L. i dr. Novyi otechestvennyi preparat triazavirin. Rezul'taty II fazy klinicheskogo ispytaniya. Voprosy virusologii. 2012; 57(6): 9-12.
21. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2011; 25(1). Available at: https://www.who.int/medicines/publications/druginformation/innlists/RecList65_final.pdf (Accessed 15.04.2020)
22. Umifenovir (Umifenovirum): instruktsiya, primenenie, protivopokazaniya i formula. Available at: https://www.rlsnet.ru/mnn_index_id_6264.htm (Data obrashcheniya: 15.04.2020)
23. Ligen Y. Handbook of COVID-19 Prevention and Treatment; 2020. Available at: https://www.researchgate.net/publication/339998871_Handbook_of_COVID-19_Prevention_and_Treatment (Accessed 15.04.2020)
24. Pshenichnaya N.Yu., Bulgakova V.A., L'vov N.I., Poromov A.A., Selelkova E.P., Grekova A.I. i dr. Klinicheskaya effektivnost' umifenovira pri grippe i ORVI (issledovanie ARBITR). Terapevticheskii arkhiv. 2019; 91(3): 56-63. DOI: http://doi.org/10.26442/00403660.2019.03.000127
25. Haviernik J., Štefánik M., Fojtíková M., Kali S., Tordo N., Rudolf I., et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018; 10(4): 184. DOI: http://doi.org/10.3390/v10040184
26. Zhang S., Zhi C., Li H., Huang D., Fan Q., Cui J., Umifenovir effectively inhibits IL-10 dependent persistent Coxsackie B4 virus infection. Antiviral. Res. 2017; 141: 165-73. DOI: http://doi.org/10.1016/j.antiviral.2017.02.018
27. Zhu Z., Lu Z., Xu T., Chen C., Yang G., Zha T., et al. Arbidol monotherapy is superior to Lopinavir/ritonavir in treating COVID-19. J. Infect. 2020; 81(1): e21-3. DOI: http://doi.org/10.1016/j.jinf.2020.03.060
28. Vremennye metodicheskie rekomendatsii. Lekarstvennaya terapiya ostrykh respiratornykh virusnykh infektsii (ORVI) v ambulatornoi praktike v period epidemii COVID-19. Versiya 1 (12.04.2020). M.; 2020. Available at: https://static-3.rosminzdrav.ru/system/attachments/attaches/000/049/991/original/RESP_REC_V1.pdf (Data obrashcheniya: 15.04.2020)
29. Du Y.X., Chen X.P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 2020. DOI: http://doi.org/10.1002/cpt.1844
30. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards influenza a virus polymerase. PLoS One. 2013; 8(7): e68347. DOI: http://doi.org/10.1371/journal.pone.0068347
31. Spravochnik lekarstv Medum.ru. AVIFAVIR – instruktsiya po primeneniyu. Available at: http://medum.ru/avifavir (Data obrashcheniya: 06.06.2020)
32. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 2002; 46(4): 977-81. DOI: http://doi.org/10.1128/aac.46.4.977-981.2002
33. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020; 209: 107512. DOI: http://doi.org/10.1016/j.pharmthera.2020.107512
34. Baranovich T., Wong S.S., Armstrong J., Marjuki H., Webby R.J., Webster R.G., et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 2013; 87(7): 3741-51. DOI: http://doi.org/10.1128/JVI.02346-12
35. Escribano-Romero E., Jiménez de Oya N., Domingo E., Saiz J.C. Extinction of West Nile virus by favipiravir through lethal mutagenesis. Antimicrob. Agents Chemother. 2017; 61(11): e01400-17. DOI: http://doi.org/10.1128/AAC.01400-17
36. Rosenke K., Feldmann H., Westover J.B., Hanley P.W., Martellaro C., Feldmann F., et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg. Infect. Dis. 2018; 24(9): 1696-9. DOI: http://doi.org/10.3201/eid2409.180233
37. Mendenhall M., Russell A., Smee D.F., Hall J.O., Skirpstunas R., Furuta Y., et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl. Trop. Dis. 2011; 5(10): e1342. DOI: http://doi.org/10.1371/journal.pntd.0001342
38. Kerber R., Lorenz E., Duraffour S., Sissoko D., Rudolf M., Jaeger A., et al. Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study. J. Infect. Dis. 2019; 220(2): 195-202. DOI: http://doi.org/10.1093/infdis/jiz078
39. Cohen J. Results from encouraging Ebola trial scrutinized. Science. 2015. DOI: http://doi.org/doi:10.1126/science.aaa7912 Available at: https://www.sciencemag.org/news/2015/02/results-encouraging-ebola-trial-scrutinized (Accessed 06.06.2020)
40. Nguyen T.H., Guedj J., Anglaret X., Laouénan C., Madelain V., Taburet A.M., et al. JIKI study group. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis. 2017; 11(2): e0005389. DOI: http://doi.org/10.1371/journal.pntd.0005389
41. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271. DOI: http://doi.org/10.1038/s41422-020-0282-0
42. Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 2020; 19(3): 149-50. DOI: http://doi.org/10.1038/d41573-020-00016-0
43. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020. DOI: http://doi.org/10.1016/j.eng.2020.03.007
44. Irie K., Nakagawa A., Fujita H., Tamura R., Eto M., Ikesue H., et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin. Transl. Sci. 2020. DOI: http://doi.org/10.1111/cts.12827
45. Reestr razreshenii na provedenie klinicheskikh issledovanii: LP Favipiravir. Available at: https://grls.rosminzdrav.ru/CiPermitionReg.aspx?PermYear=0&DateInc=&NumInc=&DateBeg=&-DateEnd=&Protocol=&RegNm=&Statement=&ProtoNum=&idCIStatementCh=&Qualifier=&CiPhase=&RangeOfApp=&Torg=%d0%a4%d0%b0%d0%b2%d0%b8%d0%bf%d0%b8%d1%80%d0%b0%d0%b2%d0%b8%d1%80&LFDos=&Producer=&Recearcher=&sponsorCountry=&MedBaseCount=&CiType=&PatientCount=&OrgDocOut=2&Status=&NotInReg=0&All=0&PageSize=8&order=date_perm&orderType=desc&pagenum=1 (Data obrashcheniya: 06.06.2020)
46. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J. Virus. Erad. 2020; 6(2): 45-51.
47. Al-Tawfiq J.A., Momattin H., Dib J., Memish Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 2014; 20: 42-6. DOI: http://doi.org/10.1016/j.ijid.2013.12.003
